|
1
|
Singh AD, Turell ME and Topham AK: Uveal
melanoma: Trends in incidence, treatment and survival.
Ophthalmology. 118:1881–1885. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vicente MA, Saornil C, García-Álvarez C,
Almaraz A, Martínez P Alonso, Frutos-Baraja JM and López-Lara F:
Uveal melanoma: Clinical characteristics, treatment and survival in
a series of 500 patients. Arch Soc Esp Oftalmol. 88:433–438. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schoenfield L: Uveal melanoma: A
pathologist's perspective and review of translational developments.
Adv Anat Pathol. 21:138–143. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jovanovic P, Mihajlovic M,
Djordjevic-Jocic J, Vlajkovic S, Cekic S and Stefanovic V: Ocular
melanoma: An overview of the current status. Int J Clin Exp Pathol.
6:1230–1244. 2013.PubMed/NCBI
|
|
5
|
Eskelin S and Kivelä T: Mode of
presentation and time to treatment of uveal melanoma in Finland. Br
J Ophthalmol. 86:333–338. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shields CL, Cater J, Shields JA, Singh AD,
Santos MC and Carvalho C: Combination of clinical factors
predictive of growth of small choroidal melanocytic tumors. Arch
Ophthalmol. 118:360–364. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Damato EM and Damato BE: Detection and
time to treatment of uveal melanoma in the United Kingdom: An
evaluation of 2,384 patients. Ophthalmology. 119:1582–1589. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Harbour JW, Augsburger JJ and Char DH:
Gene expression profiling versus TNM classification. Ophthalmology.
120:e52–e53. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sapna P: Latest developments in the
biology and management of uveal melanoma. Curr Oncol Rep.
15:509–516. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Damato B, Dopierala JA and Coupland SE:
Genotypic profiling of 452 choroidal melanomas with multiplex
ligation dependent probe amplification. Clin Cancer Res.
16:6083–6092. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Van Raamsdonk CD, Griewank KG, Crosby MB,
Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green
G, Bouvier N, et al: Mutations in GNA11 in uveal melanoma. N Engl J
Med. 363:2191–2199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Matthew G, Field J and Harbour W: Recent
developments in prognostic and predictive testing in uveal
melanoma. Curr Opin Ophthalmol. 25:234–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Selumetinib shows promise in metastatic
uveal melanoma. Cancer Discov. 3:OF82013.
|
|
14
|
Onken MD, Worley LA, Ehlers JP and Harbour
JW: Gene expression profiling in uveal melanoma reveals two
molecular classes and predicts metastatic death. Cancer Res.
64:7205–7209. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Harbour JW, Onken MD, Roberson ED, et al:
Frequent mutation of BAP1 in metastasizing uveal melanomas.
Science. 330:1410–1413. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Landreville S, Agapova OA, Matatall KA,
Kneass ZT, Onken MD, Lee RS, Bowcock AM and Harbour JW: Histone
deacetylase inhibitors induce growth arrest and differentiation in
uveal melanoma. Clin Cancer Res. 18:408–416. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Carbone M, Yang H, Pass HI, Krausz T,
Testa JR and Gaudino G: BAP1 and cancer. Nat Rev Cancer.
13:153–159. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Harbour JW, Roberson ED, Anbunathan H,
Onken MD, Worley LA and Bowcock AM: Recurrent mutations at codon
625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet.
45:133–135. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Buder K, Gesierich A, Gelbrich G and
Goebeler M: Systemic treatment of metastatic uveal melanoma: Review
of literature and future perspectives. Cancer Medicine. 2:674–686.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Falchook GS, Lewis KD, Infante JR, Gordon
MS, Vogelzang NJ, DeMarini DJ, et al: Activity of the oral MEK
inhibitor trametinib in patients with advanced melanoma: a phase 1
dose-escalation trial. Lancet Oncol. 13:782–789. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kujala E, Mäkitie T and Kivelä T: Very
long-term prognosis of patients with malignant uveal melanoma.
Invest Ophthalmol Vis Sci. 44:4651–4659. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Buzzacco DM, Abdel-Rahman MH, Park S,
Davidorf F, Olencki T and Cebulla CM: Long-term survivors with
metastatic uveal melanoma. Open Ophthalmol J. 6:49–53. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hendler K, Pe'er J, Kaiserman I, Baruch R,
Kalickman I, Barak V and Frenkel S: Trends in liver function tests:
A comparison with serum tumor markers in metastatic uveal melanoma
(part 2). Anticancer Res. 31:351–358. 2011.PubMed/NCBI
|
|
24
|
Patel SP: Latest developments in the
biology and management of uveal melanoma. Curr Oncol Rep.
15:509–516. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Harbour JW: A prognostic test to predict
the risk of metastasis in uveal melanoma based on a 15-gene
expression profile. Methods Mol Biol. 1102:427–440. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen X, Wu Q, Tan L, Porter D, Porter D,
Jager MJ, Emery C and Bastian BC: Combined PKC and MEK inhibition
in uveal melanoma with GNAQ and GNA11 mutations. Oncogene.
33:4724–4734. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ambrosini G, Musi E, Ho AL, de Stanchina E
and Schwartz GK: Inhibition of mutant GNAQ signaling in uveal
melanoma induces AMPK-dependent autophagic cell death. Mol Cancer
Ther. 12:768–776. 2013. View Article : Google Scholar : PubMed/NCBI
|
